fig4

Figure 4. BsGNP treatment reduces tumor growth. (A) Representative micro-CT image of tumor-bearing mice at 24 h after BsGNP administration (left) or a cocktail of single-antibody GNPs (right) confirmed the intratumoral accumulation of the particles (golden-yellow colored); (B) Biodistribution profile of BsGNPs at 24 h post-administration, measured via ICP-OES; mean ± SEM, n = 3; (C) Tumor growth curves for untreated and treated with BsGNP, free antibodies, or the cocktail of antibody-GNPs. Arrows indicate treatment administration days. Results presented as mean ± SEM of n = 5 mice/group. *P < 0.05, *** P < 0.001, two-way ANOVA with repeated measurements followed by Tukey’s multiple-comparisons test. Equivalent antibody doses (0.945 mg antibodies/injection) were given to free antibody-treated, cocktail-treated, and BsGNP-treated groups; (D) Body weight (% of baseline) in the untreated and treated groups measured during the treatment period. Data presented as mean ± SD of n = 5 mice/group. BsGNP: Bispecific gold nanoparticle; ID: injected dose; CT: computed tomography; ICP-OES: inductively coupled plasma optical emission spectrometry; SEM: standard error of the mean.